Pharmaceuticals
LIST1043Related Stocks
News
AstraZeneca, Bristol Myers Squibb in Merger Talks to Create Nearly $400 Billion Pharma Giant
TradingKey - British pharmaceutical giant AstraZeneca (AZN) is in talks with its U.S. peer Bristol Myers Squibb (BMY) regarding a potential merger. If a deal is reached, the combined market capitalization of the two entities would approach $400 billion, potentially creating one of the world's largest pharmaceutical groups.
Novo Nordisk Falls Over 10% in Largest Single-Day Drop in Nearly Five Months After Announcing Heart Drug Trial Failure
On July 31, Eastern Time, Novo Nordisk (NVO) fell more than 10% at one point, marking its largest single-day decline since February 23, 2026. As of press time, the stock remained down 8.84% at $47.05. Novo Nordisk announced on Friday that its high-profile investigational heart drug, ziltivekimab, failed to meet the primary endpoint in a large-scale late-stage clinical trial.
Novo Nordisk Sues Eli Lilly for False Advertising: Weight-Loss Drug Data War Escalates, GLP-1 $100 Billion Market Fight Heats Up
TradingKey - Novo Nordisk (NVO) has officially filed a lawsuit in the U.S. District Court for the District of New Jersey, alleging that Eli Lilly’s (LLY) advertisements for its blockbuster weight-loss drug Zepbound and diabetes injection Mounjaro are misleading and violate federal and state laws concerning false advertising and unfair competition. The essence of the lawsuit is a data war between the two pharmaceutical giants over the multi-hundred-billion-dollar GLP-1 drug market, where the key weapon on the battlefield is a set of clinical comparison data alleged to be "outdated."
Johnson & Johnson Delivers Bright Q2 Results, Revenue and Profit Both Beat Expectations and Guidance Raised, Pre-Market Shares Fall Against Trend
TradingKey - Global healthcare giant Johnson & Johnson (JNJ) released its second-quarter 2026 earnings report on Wednesday local time. Both revenue and earnings exceeded market expectations, and management further raised its full-year guidance. However, the company's shares fell more than 2% in pre-market trading following the announcement.
AstraZeneca Cardiomyopathy Drug Wainua Fails to Meet Late-Stage Clinical Trial Goal as Shares Plunge Over 8% Pre-Market.
TradingKey - On Thursday local time, AstraZeneca (AZN) announced the failure of a key late-stage clinical trial for its investigational drug Wainua, triggering an intraday plunge of up to 8% to $173 in US pre-market trading.
Nuvalent Surges 39% Premarket. GSK Acquires for $10.6 Billion at 40% Premium, New CEO’s First Big Bet on Lung Cancer Field
TradingKey - British pharmaceutical giant GSK announced on June 9 that it will acquire U.S. biotechnology company Nuvalent (NUVL) for $10.6 billion in an all-cash deal to bolster its lung cancer drug pipeline. This transaction marks GSK's largest acquisition in over a decade and represents the first major strategic move under new CEO Luke Miels.
